Caralee Schaefer, PhD
Caralee is a translational research scientist with 15+ years of pharmacology and drug development experience, with a particular focus on inflammation, autoimmunity, and fibrosis research. She has extensive in vivo proof-of-concept and target validation experience, including the establishment of robust and reproducible animal models for evaluating novel therapies for multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and fibrotic diseases. She has a demonstrated track record of success in project management; including the selection, partnership, and management of collaborations with CROs and academic research investigators. She has been a board member of the Inflammation Research Association since 2010, and in 2015 was elected as an officer (Secretary).
Caralee received her BA at Adrian College in Biology, and her PhD at Wayne State University in Immunology. After a post-doctoral fellowship at Parke-Davis/Warner Lambert, she joined Berlex Biosciences (1999-2007) and was responsible for leading a group of pharmacologists that evaluated novel therapeutics for inflammation, multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Caralee then joined Intermune (2008-2015), where she developed in vivo screening platforms for evaluating novel therapeutics for pulmonary, hepatic, dermal, and renal fibrosis. She coordinated a diverse team of scientists from several functional areas (chemistry, PK/ADME, cell biology, formulations, and toxicology) to accomplish in vivo proof-of-concept and target validation studies for multiple fibrosis projects. In 2019, Caralee joined Indalo Therapeutics as the Executive Director of Pharmacology.